Vaxcyte Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Vaxcyte is gedaald met een gemiddeld jaarlijks tempo van -47.2%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.3%.

Belangrijke informatie

-47.2%

Groei van de winst

28.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-14.9%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Dec 22

Vaxcyte appoints new CBO, CMO

Oct 11

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Aug 05

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Feb 25

Opbrengsten en kosten

Hoe Vaxcyte geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:PCVX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-508	82	447
30 Jun 24	-497	74	428
31 Mar 24	-437	67	369
31 Dec 23	-402	61	332
30 Sep 23	-300	55	280
30 Jun 23	-265	50	230
31 Mar 23	-245	45	196
31 Dec 22	-223	40	169
30 Sep 22	-174	35	141
30 Jun 22	-143	30	114
31 Mar 22	-118	27	93
31 Dec 21	-100	25	78
30 Sep 21	-92	23	70
30 Jun 21	-87	22	66
31 Mar 21	-83	19	67
31 Dec 20	-89	16	74
30 Sep 20	-83	14	72
30 Jun 20	-73	11	66
31 Mar 20	-64	11	57
31 Dec 19	-50	9	46
31 Dec 18	-29	5	30

Kwaliteitswinsten: PCVX is momenteel verliesgevend.

Groeiende winstmarge: PCVX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: PCVX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 47.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van PCVX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: PCVX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: PCVX heeft een negatief Return on Equity ( -14.85% ), omdat het momenteel verliesgevend is.

Vaxcyte Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Recent updates

Co-Founder notifies of intention to sell stock

Insufficient new directors

President & CFO notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

Executive VP & COO notifies of intention to sell stock

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Price target increased by 27% to US$131

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

President & CFO notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte Appoints John Furey to Board of Directors

President & CFO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

President & CFO notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Price target increased by 7.8% to US$71.14

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Co-Founder notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Senior VP notifies of intention to sell stock

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

President & CFO notifies of intention to sell stock

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Co-Founder notifies of intention to sell stock

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

President exercised options to buy US$1.1m worth of stock.

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Executive VP & COO exercised options to buy US$5.1m worth of stock.

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

Independent Director exercised options and sold US$131k worth of stock

High number of new directors

Price target increased to US$60.50

Independent Director exercised options and sold US$147k worth of stock

Price target increased to US$56.00

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte appoints new CBO, CMO

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

President & CFO notifies of intention to sell stock